Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy - Wikidata - awgldk - TriplyDB

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

http://www.wikidata.org/entity/Q37146440

about

Treatment for lupus nephritis Long-term data on tacrolimus treatment in lupus nephritis.The pathology of T cells in systemic lupus erythematosus Current status of lupus nephritis.Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.Recent clinical trials in lupus nephritis.Cyclophosphamide and lupus nephritis: when, how, for how long?Systemic lupus erythematosus: review of synthetic drugs.Renal involvement in autoimmune connective tissue diseases.ESRD from lupus nephritis in the United States, 1995-2010 An approach to validating criteria for proteinuric flare in systemic lupus erythematosus glomerulonephritis.Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis.The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease.The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.Understanding lupus nephritis: diagnosis, management, and treatment options.A Meta-Analysis on Prehypertension and Chronic Kidney Disease.Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients.American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Lupus nephritis in children - 10 years' experience.Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment.TAC-TIC use of tacrolimus-based regimens in lupus nephritis.Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions.Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians.Recent advances in the treatment of lupus nephritis.Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus.NFAT gene family in inflammation and cancer.Overview of lupus nephritis management guidelines and perspective from Asia.Top 10 developments in lupus nephritis.Overview of lupus nephritis management guidelines and perspective from Asia.Treatment of severe lupus nephritis: the new horizon.Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study.Reviewing the recommendations for lupus in children.Lupus nephritis management guidelines compared.Risk factors for renal disease in systemic lupus erythematosus and their clinical implications.IgG4-related disease and the kidney.Pharmacokinetic modeling of therapies for systemic lupus erythematosus.Lupus nephritis: an update.

P2860

Q24202572-C67E589D-F0F7-466F-895A-6DCA09D9CEA5 Q30835209-01B94BC4-7339-4AA9-B026-96E75619BE33 Q33598213-546DD4D8-CD84-4DB6-B94B-CFECE5B951BC Q33882751-3630BFEE-0DD5-4FB3-BCED-71E14459A3B3 Q33885872-0DFC7DED-4CC8-4F0C-BA71-8F7DD98B5EBB Q33924437-329B16D4-FEC2-4FE5-9DBE-2B0694F8DE66 Q34095231-D3B231D4-B581-400B-9CAE-58CF88992823 Q34498515-5738DB45-12AE-447A-92A0-FBFD023B74B3 Q34654954-2FD76045-7430-404A-9FDC-78531CDDA822 Q35051164-9EEA2AB6-E85F-4258-B486-829741E30244 Q35053510-A4474E81-D7BE-4D5D-A328-D0C32E4475DF Q35187502-3A04AF07-A3B9-41D6-8CF5-375BEAC06731 Q35574235-506564FD-C527-45F3-95E5-DE3A61C9AAC4 Q35897121-DFB516B7-8F50-4EAC-B720-DDE2AC4F564F Q36008840-BA0F4AEC-7D02-4EC4-BB6D-1217537710CF Q36036055-19BECE13-0A42-4498-83B0-9E470F859878 Q36084894-1B7410ED-827A-405F-B15F-F80343B6C3CD Q36221407-D7055475-62C9-4D89-9BF0-8F0A6DB1D9F5 Q36302245-CED8DCB1-0BB1-4C87-A45B-1C1868F6AED4 Q37399315-95C1153C-EC85-425B-B1CA-70A5330A9242 Q37403811-CA882D9B-0609-48E6-A708-3D937A81205C Q37587317-7EB56D9C-1614-4972-BE2A-3B7747EF3856 Q37671987-C5CF197E-C35A-4D20-A2E7-A438515D9BCA Q37678723-AE984785-997A-4B66-B613-2958B3BEB586 Q37857737-28554C47-7EDB-4FBA-962B-AD5C21A5E15C Q37953243-FA2C4C48-4630-4A69-9EC5-20832E9F78E3 Q37954539-B97D1B10-5FB4-43D7-86B0-1CB3F4AECBEC Q37960525-41E758CA-B1D3-47ED-91EB-F6FEA511B720 Q38040813-F71958B8-410B-480F-8463-9F4B17DA7D5A Q38123242-8872FA92-B829-4844-869E-42FC0D540CDF Q38124761-0C229E43-FCC0-4761-B088-38AB663F6802 Q38175076-B7B85B68-7809-4480-9238-A98DE7374FC2 Q38271125-6429F834-CFF5-4F39-B6A2-178AA292C4F4 Q38372154-69F096BA-9DAD-4B51-A98C-FAA40D8CED81 Q38374309-8F09883E-A9B9-4EFA-B8E4-7C4786A44211 Q38446941-CA0F343C-A2BE-4FA1-AD31-E81281879084 Q38479339-ADC9CF92-0AC4-4C66-97A9-75EE19DBAE86 Q38540095-526EC54A-943D-452F-9F3D-82FFA48016D7 Q38542910-66AC237E-8800-4C8F-9D9A-C4296FDCD79B Q38608138-D351A4B1-62F0-481E-A74D-29B083A4A356

P2860

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

http://www.wikidata.org/entity/Q37146440

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Randomized, controlled trial o ...... n lupus membranous nephropathy

@en

Randomized, controlled trial o ...... lupus membranous nephropathy.

@nl

type

label

Randomized, controlled trial o ...... n lupus membranous nephropathy

@en

Randomized, controlled trial o ...... lupus membranous nephropathy.

@nl

prefLabel

Randomized, controlled trial o ...... n lupus membranous nephropathy

@en

Randomized, controlled trial o ...... lupus membranous nephropathy.

@nl

P1433

Q37146440-DA021623-B74C-4A8F-B0B6-1BD079384C09

P1476

Q37146440-2F3385B1-5856-45F2-8B34-6DA18B2417F5

P2093

Q37146440-4AE484EE-A022-47DA-905D-52E62F5CED7E

Q37146440-690850B8-E56B-420C-BBAF-D4E5BB0A6D30

Q37146440-918A524D-279B-4A9A-A911-056C1A42C630

Q37146440-AECED8A3-53C6-419F-B240-8488FC159F4A

P2860

Q37146440-02FC4D70-E497-46BB-8F80-C3A50C11120C

Q37146440-071E6438-020E-4BA0-B679-7DA3FC0BBAFF

Q37146440-12C90978-A539-4E2E-9BCD-DF6ACFC57B34

Q37146440-137DC3C0-8348-46FF-A177-B6EB0C545BF9

Q37146440-168074DE-EFEF-4D5D-90E9-E1BBEEF3E700

Q37146440-23A3C8B7-D0B4-4936-8BEA-3C4AE0DA1FDD

Q37146440-24C3D6DB-8659-41F4-9978-849511919641

Q37146440-2BB51055-4C69-40E0-8E5C-33FE0A490948

Q37146440-2F08988E-15B6-4441-BDA3-DAEAB69BE2D0

Q37146440-414F1185-F2B4-4422-A115-F703AAEB13AB

P304

Q37146440-D692D8CA-377A-4A05-B53F-2401EE8A6D10

P31

Q37146440-F9E4EE8F-5CA2-4B88-93C7-AA21E3B1A215

P356

Q37146440-53EC5D64-2188-4110-9657-690B0AB80B49

P433

Q37146440-991530A5-44B5-4C76-BB9D-0256997A9CF5

P478

Q37146440-16476080-2364-47F5-A86A-5C0D6C8BCFC5

P577

Q37146440-9A2249F4-D7C8-4DA5-842A-9B5C030689E6

P698

Q37146440-10A11E13-D5A5-4BE3-9DBC-D3FCEAB87110

P932

Q37146440-C73AD713-63BB-4FAE-BE86-1E9BBC79F5B3

P356

P1433

Journal of the American Society of Nephrology

P1476

Randomized, controlled trial o ...... n lupus membranous nephropathy

@en

P2093

Gabor G Illei

http://www.w3.org/2001/XMLSchema#string

Howard A Austin

http://www.w3.org/2001/XMLSchema#string

James E Balow

http://www.w3.org/2001/XMLSchema#string

Michelle J Braun

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression

The 1982 revised criteria for the classification of systemic lupus erythematosus

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Cardiovascular risk factors and the long-term outcome of lupus nephritis.

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.

Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations.

The prognosis of lupus nephritis in African-Americans: a retrospective analysis.

Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature.

The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Factors affecting outcome and prognosis in membranous lupus nephropathy.

P304

901-911

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2008060665

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19297556

http://www.w3.org/2001/XMLSchema#string

P932

2663831

http://www.w3.org/2001/XMLSchema#string